Scinai Immunotherapeutics (SCNI) Common Equity (2015 - 2026)
Scinai Immunotherapeutics (SCNI) posted Common Equity of $11.8 million for Q1 2026, up 45.14% sequentially from $8.1 million in Q4 2025.
Scinai Immunotherapeutics (SCNI) Common Equity (2015 - 2026) Analysis & Trends
Scinai Immunotherapeutics has reported Common Equity for 11 years, with the latest figure at $11.8 million in Q1 2026.
- Quarterly Common Equity changed N/A year-over-year to $11.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.8 million (changed N/A YoY) and the FY2025 annual result came in at $8.1 million, down 18.78% from the prior year.
- Common Equity climbed to $11.8 million in Q1 2026 per SCNI's latest filing, from $8.1 million in the prior quarter.
- Over five years, Common Equity peaked at $11.8 million in Q1 2026 and troughed at -$7.3 million in Q2 2024.
- A 5-year average of $1.3 million and a median of -$862000.0 in 2022 frame the typical range for Common Equity.
- The sharpest annual moves came in 2023 and 2024: Common Equity slumped 458.0% in 2023, then soared 471.58% in 2024.
- Over 5 years, Common Equity stood at -$1.8 million in 2022, then slumped by 159.6% to -$4.6 million in 2023, then surged by 318.36% to $10.0 million in 2024, then decreased by 18.78% to $8.1 million in 2025, then soared by 45.14% to $11.8 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $11.8 million, $8.1 million, and $7.9 million for Q1 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Scinai Immunotherapeutics | 1.08 Mn | -3.11 Bn | -1.12 Mn | 11.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.76 Mn |
| Dec 31, 2025 | 8.10 Mn |
| Jun 30, 2025 | 7.86 Mn |
| Dec 31, 2024 | 9.98 Mn |
| Sep 30, 2024 | 10.00 Mn |
| Jun 30, 2024 | -7.28 Mn |
| Mar 31, 2024 | -5.12 Mn |
| Dec 31, 2023 | -4.57 Mn |
| Sep 30, 2023 | -2.69 Mn |
| Jun 30, 2023 | -7.11 Mn |
| Mar 31, 2023 | -4.81 Mn |
| Dec 31, 2022 | -1.76 Mn |
| Sep 30, 2022 | 2.64 Mn |
| Jun 30, 2022 | 3.26 Mn |
| Mar 31, 2022 | -862,000.00 |
| Dec 31, 2021 | 982,000.00 |
| Sep 30, 2021 | 1.30 Mn |
| Dec 31, 2020 | -15.04 Mn |
| Sep 30, 2020 | -535,000.00 |
| Jun 30, 2020 | -17.87 Mn |